Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Hepatitis B | Research

Validation of coding algorithms for identifying people with viral hepatitis using claims data according to different standard references

Authors: Ming-Jen Sheu, Tsung-Wei Chin, Fang-Ping Ku, Chung-Yi Li, Sheng-Tun Li, Tsung-Hsueh Lu

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

To assess the performance of various coding algorithms for identifying people with hepatitis B virus (HBV) and hepatitis C virus (HCV) using claims data according to different reference standards (RSs) and study periods (SPs).

Methods

A proportional random sampling of 10,000 patients aged ≥ 20 years in a health care system in Southern Taiwan were enrolled as study participants. We used three hierarchical RSs (RS1: having positive results of laboratory tests; R2: having RS1 or having prescriptions of anti-HBV or anti-HCV medications; R3: having R1 or R2 or having textual diagnosis recorded in electrical medical records) with three SPs (4-, 8-, and 12-years) to calculate positive predictive value (PPV) and sensitivity (Sen) of 6 coding algorithms using HBV- and HCV-related International Classification of Disease Tenth Revision Clinical Modification (ICD-10-CM) codes in Taiwan National Health Insurance claims data for years 2016–2019.

Results

Of 10,000 enrolled participants, the number of participants had confirmed HBV and HCV was 146 and 165, respectively according to RS1 with 4-years SP and increased to 729 and 525, respectively according to RS3 with 12-years SP. For both HBV and HCV, the PPV was lowest according to RS1 and highest according to RS3. The longer the SP, the higher the PPV. However, the Sen was highest according to RS2 with 4-years SP. For both HBV and HCV, the coding algorithm with highest PPV and Sen was “ ≥ 3 outpatient codes” and “ ≥ 2 outpatient or ≥ 1 inpatients codes,” respectively.

Conclusions

In conclusion, using different RSs with different SPs would result in different estimation of PPV and Sen. To achieve the best yield of both PPV and Sen, the optimal coding algorithm is “ ≥ 2 outpatients or ≥ 1 inpatients codes” for identifying people with HBV or HCV.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and what can it tell us. N Engl J Med. 2016;375:2293–7.CrossRef Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and what can it tell us. N Engl J Med. 2016;375:2293–7.CrossRef
2.
go back to reference Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320:867–8.CrossRef Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320:867–8.CrossRef
3.
go back to reference Basch E, Schrag D. The evolving uses of “real-world” data. JAMA. 2019;321:1359–60.CrossRef Basch E, Schrag D. The evolving uses of “real-world” data. JAMA. 2019;321:1359–60.CrossRef
4.
go back to reference Lau CS, Chen YH, Lim K, de Longueville M, Arendt C, Winthrop K. Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data. Clin Rheumatol. 2021;40:867–75.CrossRef Lau CS, Chen YH, Lim K, de Longueville M, Arendt C, Winthrop K. Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data. Clin Rheumatol. 2021;40:867–75.CrossRef
5.
go back to reference Forns X, Feld JJ, Dylla DE, Pol S, et al. Safety of patients with hepatitis C virus treated with Glecaprevir/Pibrentasvir from clinical trials and real-world cohorts. Adv Ther. 2021;22:1–8. Forns X, Feld JJ, Dylla DE, Pol S, et al. Safety of patients with hepatitis C virus treated with Glecaprevir/Pibrentasvir from clinical trials and real-world cohorts. Adv Ther. 2021;22:1–8.
7.
go back to reference Wedemeyer H, Erren P, Naumann U, Rieke A, Stoehr A, Zimmermann T, Lohmann K, König B, Mauss S. Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: real-world data from the German Hepatitis C Registry. Liver Int. 2021;41:949–55.CrossRef Wedemeyer H, Erren P, Naumann U, Rieke A, Stoehr A, Zimmermann T, Lohmann K, König B, Mauss S. Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: real-world data from the German Hepatitis C Registry. Liver Int. 2021;41:949–55.CrossRef
8.
go back to reference Müllhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly. 2021;151:w20399.PubMed Müllhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly. 2021;151:w20399.PubMed
9.
go back to reference Ehrenstein V, Petersen I, Smeeth L, et al. Helping everyone do better: a call for validation studies of routinely recorded health data. Clin Epidemiol. 2016;8:49.CrossRef Ehrenstein V, Petersen I, Smeeth L, et al. Helping everyone do better: a call for validation studies of routinely recorded health data. Clin Epidemiol. 2016;8:49.CrossRef
10.
go back to reference Chun DS, Lund JL, Stürmer T. Pharmacoepidemiology and drug safety’s special issue on validation studies. Pharmacoepidemiol Drug Saf. 2019;28:123–5.CrossRef Chun DS, Lund JL, Stürmer T. Pharmacoepidemiology and drug safety’s special issue on validation studies. Pharmacoepidemiol Drug Saf. 2019;28:123–5.CrossRef
11.
go back to reference Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies conducted using observational routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12: e1001885.CrossRef Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies conducted using observational routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12: e1001885.CrossRef
14.
go back to reference Niu B, Forde KA, Goldberg DS. Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data. Pharmacoepidemiol Drug Saf. 2015;24:107–11.CrossRef Niu B, Forde KA, Goldberg DS. Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data. Pharmacoepidemiol Drug Saf. 2015;24:107–11.CrossRef
15.
16.
go back to reference Sheu MJ, Liang FW, Li ST, Li CY, Lu TH. Validity of ICD-10-CM codes used to identify patients with chronic hepatitis B and C virus infection in administrative claims data from the Taiwan National Health Insurance outpatient claims dataset. Clin Epidemiol. 2020;12:185.CrossRef Sheu MJ, Liang FW, Li ST, Li CY, Lu TH. Validity of ICD-10-CM codes used to identify patients with chronic hepatitis B and C virus infection in administrative claims data from the Taiwan National Health Insurance outpatient claims dataset. Clin Epidemiol. 2020;12:185.CrossRef
17.
go back to reference Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L, Levine D, Reitsma JB, De Vet HC, Bossuyt PM. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6: e012799.CrossRef Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L, Levine D, Reitsma JB, De Vet HC, Bossuyt PM. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6: e012799.CrossRef
18.
go back to reference Liao CY, Wu MF, Poon SK, et al. Improving medication safety by cloud technology: progression and value-added applications in Taiwan. Int J Med Inform. 2019;126:65–71.CrossRef Liao CY, Wu MF, Poon SK, et al. Improving medication safety by cloud technology: progression and value-added applications in Taiwan. Int J Med Inform. 2019;126:65–71.CrossRef
19.
go back to reference Wu GHM, Pwu RF, Chen SC. Achieving hepatitis C elimination in Taiwan—overcoming barriers by setting feasible strategies. J Formos Med Assoc. 2018;117:1044–5.CrossRef Wu GHM, Pwu RF, Chen SC. Achieving hepatitis C elimination in Taiwan—overcoming barriers by setting feasible strategies. J Formos Med Assoc. 2018;117:1044–5.CrossRef
Metadata
Title
Validation of coding algorithms for identifying people with viral hepatitis using claims data according to different standard references
Authors
Ming-Jen Sheu
Tsung-Wei Chin
Fang-Ping Ku
Chung-Yi Li
Sheng-Tun Li
Tsung-Hsueh Lu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07212-w

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.